NO20092339L - Universal tumorcellevaksine for anti-cancer terapeutisk og profylaktisk anvendelse - Google Patents

Universal tumorcellevaksine for anti-cancer terapeutisk og profylaktisk anvendelse

Info

Publication number: NO20092339L
Authority: NO; Norway
Prior art keywords: tumor; allogeneic; adenocarcinomas; lymphomas; endometrial
Prior art date: 2006-12-20

Application number

NO20092339A

Other languages

English (en)

Norwegian (no)

Inventor

Habib Fakhrai

Daniel L Shawler

Original Assignee

Novarx

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-20

Filing date

2009-06-18

Publication date

2009-08-25

2009-06-18 Application filed by Novarx filed Critical Novarx

2009-08-25 Publication of NO20092339L publication Critical patent/NO20092339L/no

Links

239000002246 antineoplastic agent Substances 0.000 title 1
230000000069 prophylactic effect Effects 0.000 title 1
229940030325 tumor cell vaccine Drugs 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 4
230000000735 allogeneic effect Effects 0.000 abstract 3
206010025323 Lymphomas Diseases 0.000 abstract 2
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
208000009956 adenocarcinoma Diseases 0.000 abstract 2
210000000481 breast Anatomy 0.000 abstract 2
210000003169 central nervous system Anatomy 0.000 abstract 2
210000001072 colon Anatomy 0.000 abstract 2
230000002357 endometrial effect Effects 0.000 abstract 2
230000000762 glandular Effects 0.000 abstract 2
239000003018 immunosuppressive agent Substances 0.000 abstract 2
229940125721 immunosuppressive agent Drugs 0.000 abstract 2
210000004072 lung Anatomy 0.000 abstract 2
201000001441 melanoma Diseases 0.000 abstract 2
230000002611 ovarian Effects 0.000 abstract 2
210000000496 pancreas Anatomy 0.000 abstract 2
210000002307 prostate Anatomy 0.000 abstract 2
210000000130 stem cell Anatomy 0.000 abstract 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 2
210000001685 thyroid gland Anatomy 0.000 abstract 2
210000001519 tissue Anatomy 0.000 abstract 2
210000004881 tumor cell Anatomy 0.000 abstract 2
201000009030 Carcinoma Diseases 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000003679 cervix uteri Anatomy 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
210000003734 kidney Anatomy 0.000 abstract 1
230000003248 secreting effect Effects 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO20092339A 2006-12-20 2009-06-18 Universal tumorcellevaksine for anti-cancer terapeutisk og profylaktisk anvendelse NO20092339L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87622206P	2006-12-20	2006-12-20
PCT/US2007/088457 WO2008105978A1 (en)	2006-12-20	2007-12-20	Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization

Publications (1)

Publication Number	Publication Date
NO20092339L true NO20092339L (no)	2009-08-25

Family

ID=39233098

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20092339A NO20092339L (no)	2006-12-20	2009-06-18	Universal tumorcellevaksine for anti-cancer terapeutisk og profylaktisk anvendelse

Country Status (15)

Country	Link
US (2)	US8293252B2 (pt)
EP (2)	EP2101812A1 (pt)
JP (2)	JP2010514697A (pt)
KR (1)	KR20090107507A (pt)
AU (1)	AU2007347689B2 (pt)
BR (1)	BRPI0720689A2 (pt)
CA (1)	CA2673607A1 (pt)
EA (1)	EA017613B1 (pt)
ES (1)	ES2547958T3 (pt)
HU (1)	HUE027617T2 (pt)
MX (1)	MX2009006691A (pt)
NO (1)	NO20092339L (pt)
NZ (1)	NZ578181A (pt)
SG (1)	SG192304A1 (pt)
WO (1)	WO2008105978A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2342334A4 (en) *	2008-09-29	2012-03-14	Univ Pennsylvania	VACCINES DIRECTED TO TUMOR VESSEL MARKERS
US20130225659A1 (en) *	2010-07-19	2013-08-29	Isis Pharmaceuticals, Inc.	Modulation of nuclear-retained rna
WO2012156969A1 (en)	2011-05-17	2012-11-22	Hadasit Medical Research Services And Development Ltd.	Allogeneic tumor cell vaccination
US20130095575A1 (en) *	2011-10-03	2013-04-18	The Board Of Trustees Of The Leland Stanford Junior University	Methods for Fractionation, Analysis and Collection of Microvesicles From Patient Samples
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
AU2018214979A1 (en) *	2017-02-01	2019-08-15	Acceleron Pharma Inc.	TGFβ and actrii antagonists for use in increasing immune activity
EP3999112A4 (en) *	2019-07-19	2023-08-23	Dana-Farber Cancer Institute, Inc.	TUMOR VACCINE COMPOSITIONS AND METHODS OF USE THEREOF FOR THE PREVENTION AND/OR TREATMENT OF CANCER
JP2023504659A (ja) *	2019-12-03	2023-02-06	ニューボーゲン，インコーポレイティド	腫瘍細胞ワクチン
CN111351942B (zh) *	2020-02-25	2024-03-26	北京尚医康华健康管理有限公司	肺癌肿瘤标志物筛选系统及肺癌风险分析系统
AU2021368780A1 (en) *	2020-11-02	2023-06-22	Neuvogen, Inc.	Tumor cell vaccines
EP4396352A4 (en)	2021-09-01	2025-10-01	Ionis Pharmaceuticals Inc	COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5772995A (en)	1994-07-18	1998-06-30	Sidney Kimmel Cancer Center	Compositions and methods for enhanced tumor cell immunity in vivo
AU2001231204A1 (en) *	2000-01-27	2001-08-07	Sidney Kimmel Cancer Center	Genetically engineered tumor cell vaccines
ES2373431T3 (es) *	2000-03-31	2012-02-03	Novarx	Células genéticamente modificadas que expresan un inhibidor de tgf-beta, siendo las células células de cáncer de pulmón.
US6984522B2 (en) *	2000-08-03	2006-01-10	Regents Of The University Of Michigan	Isolation and use of solid tumor stem cells
GB0406215D0 (en) *	2004-03-19	2004-04-21	Procure Therapeutics Ltd	Prostate stem cell

2007
- 2007-12-20 ES ES11184308.2T patent/ES2547958T3/es active Active
- 2007-12-20 NZ NZ578181A patent/NZ578181A/en not_active IP Right Cessation
- 2007-12-20 BR BRPI0720689-5A2A patent/BRPI0720689A2/pt not_active IP Right Cessation
- 2007-12-20 MX MX2009006691A patent/MX2009006691A/es not_active Application Discontinuation
- 2007-12-20 HU HUE11184308A patent/HUE027617T2/en unknown
- 2007-12-20 SG SG2012005021A patent/SG192304A1/en unknown
- 2007-12-20 EP EP07873860A patent/EP2101812A1/en not_active Withdrawn
- 2007-12-20 JP JP2009543236A patent/JP2010514697A/ja not_active Withdrawn
- 2007-12-20 EP EP11184308.2A patent/EP2404614B1/en not_active Not-in-force
- 2007-12-20 AU AU2007347689A patent/AU2007347689B2/en not_active Ceased
- 2007-12-20 WO PCT/US2007/088457 patent/WO2008105978A1/en not_active Ceased
- 2007-12-20 CA CA002673607A patent/CA2673607A1/en not_active Abandoned
- 2007-12-20 US US12/520,485 patent/US8293252B2/en not_active Expired - Fee Related
- 2007-12-20 EA EA200970607A patent/EA017613B1/ru not_active IP Right Cessation
- 2007-12-20 KR KR1020097015217A patent/KR20090107507A/ko not_active Ceased
2009
- 2009-06-18 NO NO20092339A patent/NO20092339L/no not_active Application Discontinuation
2012
- 2012-10-23 US US13/658,688 patent/US20130064856A1/en not_active Abandoned
2013
- 2013-03-29 JP JP2013071300A patent/JP2013129677A/ja active Pending

Also Published As

Publication number	Publication date
US8293252B2 (en)	2012-10-23
WO2008105978A1 (en)	2008-09-04
EA017613B1 (ru)	2013-01-30
EA200970607A1 (ru)	2010-04-30
AU2007347689A1 (en)	2008-09-04
MX2009006691A (es)	2009-09-09
US20130064856A1 (en)	2013-03-14
CA2673607A1 (en)	2008-09-04
HUE027617T2 (en)	2016-11-28
SG192304A1 (en)	2013-08-30
EP2101812A1 (en)	2009-09-23
ES2547958T3 (es)	2015-10-09
BRPI0720689A2 (pt)	2014-02-25
AU2007347689A2 (en)	2009-07-30
JP2013129677A (ja)	2013-07-04
AU2007347689B2 (en)	2013-08-15
EP2404614A1 (en)	2012-01-11
NZ578181A (en)	2012-02-24
EP2404614B1 (en)	2015-06-17
US20100047289A1 (en)	2010-02-25
JP2010514697A (ja)	2010-05-06
KR20090107507A (ko)	2009-10-13

Legal Events

Date	Code	Title	Description
2015-07-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20092339L (no)	2009-08-25	Universal tumorcellevaksine for anti-cancer terapeutisk og profylaktisk anvendelse
MX2024003385A (es)	2024-04-05	Compuestos de pirazina y usos de los mismos.
MX2021001508A (es)	2021-07-02	Proteínas de unión multiespecífica que se unen a her2, nkg2d y cd16 y métodos de uso.
MX9702530A (es)	1998-02-28	Ligandos tie-2, metodos de preparacion y usos de los mismos.
EP4495597A3 (en)	2025-04-30	Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
MY202279A (en)	2024-04-22	Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2021002998A (es)	2021-05-14	Compuestos de triazolo-pirimidina y usos de los mismos.
EP4527466A3 (en)	2025-06-18	Anti-dll3 chimeric antigen receptors and uses thereof
ECSP099523A (es)	2009-09-29	Antagonistas específicos de VEGF para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadíos tempranos
EA201700181A1 (ru)	2017-09-29	Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
WO2020076969A3 (en)	2020-07-23	Anti-lap antibody variants and uses thereof
WO2021090062A8 (en)	2022-04-28	Anti-mesothelin eribulin antibody-drug conjugates and methods of use
EA201070636A1 (ru)	2010-10-29	Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
WO2014008206A3 (en)	2014-02-27	DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E
IL176007A0 (en)	2006-10-05	Antibodies specific to c35 and pharmaceutical compositions containing the same
JOP20240288A1 (ar)	2024-12-23	أجسام مضادة لـ ror1 ومتقارنات الأجسام المضادة، تركيبات تحتوي على أجسام مضادة لـ ror1 أو متقارنات الأجسام المضادة، وطرق تصنيع واستخدام الأجسام المضادة لـ ror1 ومتقارنات الأجسام المضادة
JP2010514697A5 (pt)	2011-12-15
MX2021010288A (es)	2021-09-23	Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
WO2004031231A3 (en)	2004-07-08	Genes and polypeptides relating to prostate cancers
Bellmunt	2015	Bladder Cancer, An Issue of Hematology/Oncology Clinics of North America
MX2009001014A (es)	2009-06-22	Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie.
Alshaibi et al.	2022	Studying the anticancer effects of thymoquinone on breast cancer cells through natural killer cell activity
WO2014145817A3 (en)	2014-12-31	Novel therapeutic target for the treatment of cancers and related therapies and methods
WO2007059190A3 (en)	2008-10-23	Compositions of and methods of using stabilized psma dimers
EP4656196A3 (en)	2026-03-04	T cell receptors targeting pik3ca mutations and uses thereof